Dynamics of BCR-ABL mRNA expression in first-line therapy of chronic myelogenous leukemia patients with imatinib or interferon alpha/ara-C
Dynamics of BCR-ABL mRNA expression in first-line therapy of chronic myelogenous leukemia patients with imatinib or interferon alpha/ara-C
We sought to determine dynamics of BCR-ABL mRNA expression levels in 139 patients with chronic myelogenous leukemia (CML) in early chronic phase, randomized to receive imatinib (n=69) or interferon (IFN)/Ara-C (n=70). The response was sequentially monitored by cytogenetics from bone marrow metaphases (n=803) and qualitative and quantitative RT-PCR from peripheral blood samples (n=1117). Complete cytogenetic response (CCR) was achieved in 60 (imatinib, 87%) vs 10 patients (IFN/Ara-C, 14%) after a median observation time of 24 months. Within the first year after CCR, best median ratio BCR-ABL/ABL was 0.087%, (imatinib, n=48) vs 0.27% (IFN/Ara-C, n=9, P=0.025). BCR-ABL was undetectable in 25 cases by real-time PCR, but in only four patients by nested PCR. Median best response in patients with relapse after CCR was 0.24% (n=3) as compared to 0.029% in patients with continuous remission (n=52, P=0.029). We conclude that (i) treatment with imatinib in newly diagnosed CML patients is associated with a rapid decrease of BCR-ABL transcript levels; (ii) nested PCR may reveal residual BCR-ABL transcripts in samples that are negative by real-time PCR; (iii) BCR-ABL transcript levels parallel cytogenetic response, and (iv) imatinib is superior to IFN/Ara-C in terms of the speed and degree of molecular responses, but residual disease is rarely eliminated.
epidemiology, male, fusion proteins, chronic, cytogenetics, antineoplastic agents, interferon-alpha, multicenter studies, cytarabine, germany, diagnosis, messenger, disease, middle aged, antineoplastic, recurrence, research support, patients, piperazines, treatment outcome, female, blood, prospective studies, metaphase, myeloid, genetics, proteins, prognosis, bone, bcr-abl, cross-over studies, protein, pyrimidines, non-U.S.gov't, humans, antimetabolites, leukemia, rna, bone marrow, aged, time, metabolism, observation, administration & dosage, adult, comparative study, therapy, risk factors, drug therapy
2392-2400
Muller, M.C.
f443fd83-3203-42b1-a110-3532d65f2a2e
Gattermann, N.
d23fdb88-810e-4a56-af55-ddcbb2e57961
Lahaye, T.
97333448-5919-4fa2-b1d7-d4bcc51733f3
Deininger, M.W.
1432757e-04e8-4426-8ead-83bfd1a655f5
Berndt, A.
7b346490-236d-458a-8224-e5d8ca0ca0d4
Fruehauf, S.
4dbbc11f-8ab7-4cc4-b508-35a2d190bb84
Neubauer, A.
8463ae1b-e70e-4176-9bc2-b83184e40561
Fischer, T.
aba70ee0-35f0-416e-a436-658edcd9b1eb
Hossfeld, D.K.
ef5b628a-3e37-4705-a211-7a314de57042
Schneller, F.
4c3a5379-5858-4abd-8f17-75b9f5d48a7e
Krause, S.W.
b6ec5c16-fd7a-409c-9dc3-613c89771f90
Nerl, C.
a3e4aed3-20e0-4928-9ff2-0e77175a9742
Sayer, H.G.
d7fdb285-ed5f-455f-9265-0a7a36158196
Ottmann, O.G.
b5909f66-cc4e-462e-8aef-66ded21ecf07
Waller, C.
f8fe1021-bff0-4a61-b7a3-abd6283b51f3
Aulitzky, W.
0682ba7b-4e4b-43fe-bd8d-78b69313f4a6
Le Coutre, P.
5ed4a3ef-f787-4950-b8ae-38103811fea6
Freund, M.
689ed2f3-5458-4858-a1ab-4a5ca4c99749
Merx, K.
119693a0-18cb-4474-83d1-776c685ccac8
Paschka, P.
3a97b303-face-4de6-8a34-e3c6bd98c0f9
Konig, H.
9bfea440-ff35-43c8-b326-39e0917ab71a
Kreil, S.
2404ac13-cdaa-43a3-913b-adceb79e598f
Berger, U.
440811e1-e1c2-4f54-a435-b6dd61853857
Gschaidmeier, H.
46d97d80-f9c6-4286-af8a-407d4a282058
Hehlmann, R.
753d719b-7bf8-4f74-bfdc-6d5d47e5d2c7
Hochhaus, A.
4c0b9da4-adfa-4253-8af7-78cec9e9a24f
2003
Muller, M.C.
f443fd83-3203-42b1-a110-3532d65f2a2e
Gattermann, N.
d23fdb88-810e-4a56-af55-ddcbb2e57961
Lahaye, T.
97333448-5919-4fa2-b1d7-d4bcc51733f3
Deininger, M.W.
1432757e-04e8-4426-8ead-83bfd1a655f5
Berndt, A.
7b346490-236d-458a-8224-e5d8ca0ca0d4
Fruehauf, S.
4dbbc11f-8ab7-4cc4-b508-35a2d190bb84
Neubauer, A.
8463ae1b-e70e-4176-9bc2-b83184e40561
Fischer, T.
aba70ee0-35f0-416e-a436-658edcd9b1eb
Hossfeld, D.K.
ef5b628a-3e37-4705-a211-7a314de57042
Schneller, F.
4c3a5379-5858-4abd-8f17-75b9f5d48a7e
Krause, S.W.
b6ec5c16-fd7a-409c-9dc3-613c89771f90
Nerl, C.
a3e4aed3-20e0-4928-9ff2-0e77175a9742
Sayer, H.G.
d7fdb285-ed5f-455f-9265-0a7a36158196
Ottmann, O.G.
b5909f66-cc4e-462e-8aef-66ded21ecf07
Waller, C.
f8fe1021-bff0-4a61-b7a3-abd6283b51f3
Aulitzky, W.
0682ba7b-4e4b-43fe-bd8d-78b69313f4a6
Le Coutre, P.
5ed4a3ef-f787-4950-b8ae-38103811fea6
Freund, M.
689ed2f3-5458-4858-a1ab-4a5ca4c99749
Merx, K.
119693a0-18cb-4474-83d1-776c685ccac8
Paschka, P.
3a97b303-face-4de6-8a34-e3c6bd98c0f9
Konig, H.
9bfea440-ff35-43c8-b326-39e0917ab71a
Kreil, S.
2404ac13-cdaa-43a3-913b-adceb79e598f
Berger, U.
440811e1-e1c2-4f54-a435-b6dd61853857
Gschaidmeier, H.
46d97d80-f9c6-4286-af8a-407d4a282058
Hehlmann, R.
753d719b-7bf8-4f74-bfdc-6d5d47e5d2c7
Hochhaus, A.
4c0b9da4-adfa-4253-8af7-78cec9e9a24f